Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2002 Nov 12;11(2):123–148. doi: 10.1016/0165-2427(86)90093-0

Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective

NC Pedersen 1, L Johnson 1, D Birch 2, GH Theilen 2
PMCID: PMC7125533  PMID: 3008409

Abstract

Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70. Kittens vaccinated with envelope proteins and infected with feline sarcoma virus (FeSV) developed smaller tumors than nonvaccinates, but a greater incidence of persistent retroviremia. Similarly, FeLV-gp70 and -gp85 vaccinated kittens were more apt to become persistently retroviremic following virulent FeLV challenge exposure than nonvaccinates.

Kittens vaccinated with inactivated whole FeLV developed smaller tumors after FeSV inoculation and had a lower incidence of persistent retroviremia than nonvaccinates. The protective effect of inactivated whole FeLV vaccine against persistent retroviremia was also seen with FeLV challenge-exposed cats. Protection afforded by inactivated whole FeLV vaccine was not associated with virus neutralizing antibodies, although ELISA antibodies to both whole FeLV and FeLV-gp70 were induced by vaccination.

References

  1. Azocar J., McLaine M.F., Essex M. Neutralization of feline retrovirus with antisera to normal cell alloantigens. In: Hardy W.D. Jr., Essex M., McClelland A.J., editors. Feline Leukemia Virus. Elsevier/North-Holland Publishing Co; Amsterdam: 1980. pp. 253–260. [Google Scholar]
  2. Bittle J.L., Houghton R.A., Alexander H., Shinnick T.M., Sutcliffe J.G., Lerner R.A., Rowlands D.J., Brown F. Protection against footand-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature. 1982;5869:30–33. doi: 10.1038/298030a0. [DOI] [PubMed] [Google Scholar]
  3. Bradford M.M. A rapid and sensitive method for quantitation of protein utilizing the principle of protein dye binding. Anal. Biochem. 1976;72:248. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Brown B.W., Jr., Hollander M. John Wiley and Sons; New York: 1977. Statistics: A biomedical introduction; pp. 109–129. [Google Scholar]; Brown B.W., Jr., Hollander M. John Wiley and Sons; New York: 1977. Statistics: A biomedical introduction; pp. 173–194. [Google Scholar]
  5. Bruck C., Portetelle D., Glineur C., Bollen A. One-step purification of mouse monoclonal antibodies from ascitic fluid by DEAE affi-gel blue chromatography. J. Immunol. Methods. 1982;53:313–319. doi: 10.1016/0022-1759(82)90178-8. [DOI] [PubMed] [Google Scholar]
  6. Cuatrecasas P. Protein purification by affinity chromatography. J. Biol. Chem. 1971;245:3059–3065. [PubMed] [Google Scholar]
  7. deNoronha F., Grant C.K., Essex M., Bolognesi D.P. Passive immune serotherapy protects cats from disseminated FeSV-induced Fibrosarcomas. In: Hardy W.D. Jr., Essex M., McClelland A.J., editors. Feline Leukemia Virus. Elsevier/North-Holland Publishing Co; Amsterdam: 1980. pp. 253–260. [Google Scholar]
  8. deNoronha R., Grant C.K., Lutz H., Keyes A. Circulating levels of feline leukemia and sarcoma viruses and fibrosarcoma regression in persistently viremic cats. Cancer Res. 1983;43:1663–1668. [PubMed] [Google Scholar]
  9. Egerton J.R., Laing E.A., Thorley C.M. Effect of Quil A a saponin derivitive, on the response of sheep to alum precipitated Bacteroides nodosus vaccines. Vet. Sci. Comm. 1978;2:247–252. [Google Scholar]
  10. Fishinger P.J., Blevins C.S., Nomura S. Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J. Virol. 1974;14:177–179. doi: 10.1128/jvi.14.1.177-179.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Glantz S.A. McGraw-Hill Co; New York: 1981. Primer of Biostatistics; pp. 114–117. [Google Scholar]
  12. Grant D.C., deNoronha R., Tusch C., Michalek M.T., McLane M.F. Protection of cats against progressive fibrosarcoma and persistent leukemia virus infection by vaccination with feline leukemia cells. J. Natl. Cancer Inst. 1980;65:1285–1292. [PubMed] [Google Scholar]
  13. Hardy W.D., Jr. The feline leukemia virus. J. Amer. Anim. Hosp. Assoc. 1981;17:951–980. [Google Scholar]
  14. Hoover E.A., Schaller J.P., Mathes L.E., Olsen R.G. Passive immunity to feline leukemia: Evaluation of immunity from dams naturally infected and experimentally vaccinated. Infect. Immun. 1977;16:54–59. doi: 10.1128/iai.16.1.54-59.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hunsmann G., Maenning V., Schafer W. Properties of mouse leukemia viruses. IX. Active and passive immunization of mice against Friend leukemia with isolated viral gp71 glycoprotein and its corresponding antiserum. Virology. 1975;66:327–329. doi: 10.1016/0042-6822(75)90203-2. [DOI] [PubMed] [Google Scholar]
  16. Hunsmann G., Pedersen N.C., Theilen G.H., Bayer H. Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of viral-induced feline sarcoma. Med. Microbiol. Immunol. 1983;171:233–241. doi: 10.1007/BF02123497. [DOI] [PubMed] [Google Scholar]
  17. Hunsmann G., Schneider J., Schultz A. Immunoprevention of Friend virus induced erythroleukemia by vaccination with envelope glycoprotein complexes. Virol. 1981;113:602–612. doi: 10.1016/0042-6822(81)90188-4. [DOI] [PubMed] [Google Scholar]
  18. Jarrett W., Jarrett O., Mackey L., Laird H., Hood C., Hay D. Vaccination against feline leukemia virus using a cell membrane antigen system. J. Cancer. 1975;16:124–141. doi: 10.1002/ijc.2910160115. [DOI] [PubMed] [Google Scholar]
  19. Jarrett W.F., Mackey L., Jarret O., Laird H., Hood C. Antibody response and virus survival in cats vaccinated against feline leukemia. Nature. 1976;248:230–232. doi: 10.1038/248230a0. [DOI] [PubMed] [Google Scholar]
  20. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  21. Lerner R.A. Synthetic vaccines. Sci. Amer. 1983;242(2):66–74. doi: 10.1038/scientificamerican0283-66. [DOI] [PubMed] [Google Scholar]
  22. Lewis M.G., Mathes L.E., Olsen R.G. Protection against feline leukemia by vaccination with a subunit vaccine. Infect. Immun. 1981;34:888–894. doi: 10.1128/iai.34.3.888-894.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lutz H., Pedersen N.C., Durbin R., Theilen G.H. Monoclonal antibodies to three epitopic regions of feline leukemia virus p27 and their use in enzyme-linked immunosorbent assay of p27. J. Immun. Methods. 1983;56:209–220. doi: 10.1016/0022-1759(83)90413-1. [DOI] [PubMed] [Google Scholar]
  24. Lutz H., Pedersen N.C., Higgins J., Troy F.A., Theilen G.H. Viruses in Naturally Occurring Cancers. Vol 7. 1982. Long-term immune response to feline leukemia virus components in cats after natural infection; pp. 653–664. (Cold Springs Harbor Conferences on Cell Proliferation). [Google Scholar]
  25. Massey R.J., Schochetman G. Viral epitopes and monoclonal antibodies: Isolation of blocking antibodies that inhibit virus neutralization. Science. 1981;213:447–449. doi: 10.1126/science.6264601. [DOI] [PubMed] [Google Scholar]
  26. Mathes L.E., Lewis M.G., Olsen R.G. Immunoprevention of feline leukemia: Efficacy testing and antigenic analysis of soluble tumor-cell antigen vaccine. In: Hardy W.D. Jr., Essex M., McClelland A.J., editors. Feline Leukemia Virus. Elsevier/North-Holland; New York: 1981. pp. 211–216. [Google Scholar]
  27. Mathes L.E., Olsen R.G., Hebebrand L.C., Hoover E.A., Schaller J.P., Adams P.W., Nichols W.S. Immunosuppressive properties of a virion polypeptide, a 15,000 dalton protein, from feline leukemia virus. Cancer Res. 1979;39:950–955. [PubMed] [Google Scholar]
  28. Nunberg J.H., Rodgers G., Gilbert J.H., Snead R.M. Vol. 81. 1984. Method to map antigenic determinants recognized by monoclonal antibodies: Localization of a determinant of virus neutralization on the feline leukemia virus envelope protein gp70; pp. 3675–3679. (Proc. Natl. Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Olsen R.G., Hoover E.A., Mathes L.E., Heding L., Schaller J.P. Immunization against feline oncornavirus disease using a killed tumor cell vaccine. Cancer Res. 1976;36:3642–3646. [PubMed] [Google Scholar]
  30. Olsen R.G., Hoover E.A., Schaller J.P., Mathes L.E., Wolff L.H. Abrogation of resistance to feline oncornavirus disease by immunization with killed feline leukemia virus. Cancer Res. 1977;37:2082–2085. [PubMed] [Google Scholar]
  31. Onuma M., Hodatsu T., Yamamoto S., Hyashihara M., Masu S., Mikami T., Izawa H. Protection by vaccination against bovine leukemia virus infection in sheep. Amer. J. Vet. Res. 1984;45:1212–1215. [PubMed] [Google Scholar]
  32. Osterhaus A., Weijer K., Uytdehaag F., Jarrett O., Sundquist B., Morein B. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. J. Virol. 1985;135:591–596. [PubMed] [Google Scholar]
  33. Pedersen N.C., Black J.W. Attempted immunization of cats against feline infectious peritonitis using either avirulent live virus or sublethal amounts of virulent virus. Am. J. Vet. Res. 1983;44:229–234. [PubMed] [Google Scholar]
  34. Pedersen N.C., Boyle J.F. Immunologic phenomena in the effusive farm of feline infectious peritonitis. Am. J. Vet. Res. 1980;41:868–876. [PubMed] [Google Scholar]
  35. Pedersen N.C., Johnson L., Theilen G.H. Biological behavior of tumors and associated retroviremia in cats inoculated with Snyder-Theilen fibrosarcoma virus and the phenomena of tumor recurrence after primary regression. Infect. Immun. 1984;43:631–636. doi: 10.1128/iai.43.2.631-636.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pedersen N.C., Madewell B.R. Feline leukemia virus disease complex. In: Kirk R.W., editor. VII. W.B. Saunders, Co; Philadelphia: 1980. pp. 404–410. (Current Veterinary Therapy). [Google Scholar]
  37. Pedersen N.C., Meric S.M., Ho E., Johnson L., Plucker S., Theilen G.H. The clinical significance of latent feline leukemia virus infection in cats. Feline Pract. 1984;14(2):32–48. [Google Scholar]
  38. Pedersen N.C., Theilen G., Keane M.A., Fairbanks L., Mason T., Orser B., Chen C., Allison C. Studies of naturally transmitted feline leukemia virus infection. Amer. J. Vet. Res. 1977;38:1523–1532. [PubMed] [Google Scholar]
  39. Pedersen N.C., Theilen G.H., Werner L.L. Safety and efficacy studies of live and killed-feline leukemia virus vaccines. Amer. J. Vet. Res. 1978;40:1120–1126. [PubMed] [Google Scholar]
  40. Porterfield J.S. Immunological enhancement and the pathogenesis of dengue hemorrhagic fever. J. Hyg. (Cambridge) 1982;89:355–364. doi: 10.1017/s0022172400070923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rasheed S., Gardner M.B. Isolation of feline leukemia virus from a leopard cat cell line and search for retrovirus in wild felidae. J. Natl. Cancer Inst. 1981;67:929–933. [PubMed] [Google Scholar]
  42. Rickard C.G., Post J.E., deNoronha F., Barr L.M. A transmissible virus-induced lymphocytic leukemia of the cat. J. Natl. Cancer Inst. 1969;42:987–1014. [PubMed] [Google Scholar]
  43. Rojko J.L., Hoover E.A., Mathes L.E., Olsen R.G., Schaller J.P. Pathogenesis of experimental feline leukemia virus infections. J. Natl. Cancer Inst. 1978;63:759–768. doi: 10.1093/jnci/63.3.759. [DOI] [PubMed] [Google Scholar]
  44. Salerno R.A., Lehman E.D., Larson V.M., Hilleman R.A. Feline leukemia virus envelope glycoprotein vaccine: Preparation and evaluation of immunizing potency in guinea pigs and cat. J. Natl. Cancer Inst. 1978;61:1487–1494. [PubMed] [Google Scholar]
  45. Sarma P.S., Log T. Subgroup classification of feline leukemia viruses by viral interference and neutralization tests. Virol. 1973;54:1606–1609. doi: 10.1016/0042-6822(73)90125-6. [DOI] [PubMed] [Google Scholar]
  46. Schneider J., Falk H., Hunsmann G. Envelope polypeptides of Friend leukemia virus: Purification and structural analysis. J. Virol. 1980;33:597–605. doi: 10.1128/jvi.33.2.597-605.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Theilen G.H., Kawaakami T.G., Rush J.D., Munn R.J. Replication of cat leukemia virus cell suspension cultures. Nature. 1969;222:549. doi: 10.1038/222589b0. [DOI] [PubMed] [Google Scholar]
  48. Towbin H., Staehelin T., Gordon J. Vol. 76. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications; pp. 4350–4354. (Proc Natl. Inst. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yohn D.S., Olsen R.G., Schaller J.P., Hoover E.A., Mathes L.E., Heding L., Davis G.W. Experimental oncornavirus vaccines in the cat. Cancer Res. 1976;36:646–651. [PubMed] [Google Scholar]

Articles from Veterinary Immunology and Immunopathology are provided here courtesy of Elsevier

RESOURCES